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In this article authors presented a retrospective cohort study on pioglitazone use and PD incidence by using a large Asian population-based dataset in Taiwan. The data of 7906 patients with diabetes using pioglitazone was compared with the data of 7906 patients with diabetes not receiving pioglitazone. PD occurred in 257 (1.63%): 119 (1.51%) pioglitazone users and 138 (1.75%) nonusers. The adjusted HR for PD within the follow-up period was 0.93 (95% confidence interval [CI] : 0.73-1.19) in the patients who had received pioglitazone compared with the matched patients who had not received pioglitazone.
Authors thought this retrospective cohort study failed to determine the relationship between pioglitazone use and PD incidence, regardless of sex, among an Asian population of patients with diabetes overall this is a useful paper about thiazolidinedione and PD. The authors need to consider/ reassess the following points: Response: Thank you for the suggestions. The contradictory findings could be the result of several inherent limitations, such as ethnicity variance, information deficiency, and study strategy difference. We have addressed relevant statements in Discussion as follows: "These contradictory findings could be the result of several inherent limitations, such as ethnicity variance, information deficiency, and study strategy difference. For instance, both of the aforementioned two studies analyzed Western patient populations.29,30 By contrast, the present study analyzed an Asian population to investigate the association between pioglitazone use and PD. In previous literature, the frequency of the PPAR-γ Pro12Ala polymorphism varies from 2% to 25% depending on race/ethnicity. The frequency is relatively high in Caucasians (about 20%); however, it is as low as 1-3% in Asian and African population.31Accordingly, genetic and environmental factors in Asian populations may be different from those in Western populations. In addition, the aforementioned study conducted in Norway did not consider some potential risk factors and comorbidities in the analyses30; such an information deficiency could affect the connection between pioglitazone use and PD. Furthermore, the aforementioned study conducted in the United Kingdom indicated that the observed preventive association was limited to cases of thiazolidinedione treatment and did not consider relative long-term benefits.29 Moreover, further analysis revealed that pioglitazone use did not reduce the risk of PD.29" (1st paragraph, page 12) 6. Is there any effect of the pioglitazone dose? What was the dose of pioglitazone applied to patients?
Response: Thank you for the suggestions. We have performed a dose-dependent analysis to determine whether pioglitazone dose was associated with PD. The findings were presented in Table  4 . We have addressed relevant methodology in Methods as follows: "This study further conducted a dose-dependent analysis to investigate whether pioglitazone exposure strength was associated with PD. The cumulative defined daily dose (cDDD) was calculated as the sum of dispensed DDD of statins during 5-year study period in this study. We categorized the patients receiving pioglitazone into two levels according to the median dose (median cDDD=365)." (2nd paragraph, page 7)
The relevant statements were shown in Results as follows: " Table 4 shows the findings regarding dose-dependent analysis. It reveals the HRs for Parkinson's disease among patients with diabetes during a 5-year follow-up period, stratified by the cumulative defined daily dose (cDDD) of pioglitazone. We failed to observe the relationship between pioglitazone use and PD incidence in both high and low cumulative dose of pioglitazone. The adjusted HRs for PD occurrence were 0.94 (95% CI: 0.66-1.34) and 0.82 (95% CI: 0.59-1.15), respectively, for patients receiving high cumulative dose of pioglitazone (≥365 cDDD) and low cumulative dose of pioglitazone (<365 cDDD)." (3nd paragraph, page 10)
MINOR PROBLEMS: 1. The edition of manuscript should be improved -double space should be eliminated or when needed added (lack of spaces). The language should be improved.
Response: Thank you for the comments. As suggested, we have eliminated the double space in the manuscript. In addition, this manuscript has been thoroughly copyedited by a professional copyediting service (We have provided the English Editing Certificate). Thank you again for offering so many valuable comments and guidance. They are very helpful for us on revising this manuscript.
Reviewer: 3 Reviewer Name: Gao Chen Institution and Country: Zhejiang University School of Medicine, China Authors thought this retrospective cohort study failed to determine the relationship between pioglitazone use and PD incidence, regardless of sex, among an Asian population of patients with diabetes overall this is a useful paper about thiazolidinedione and PD. The authors need to consider/ reassess the following points: 1. two samples were just matched on sex and age, other medication use such as aspirin, statins and angiotensin receptor blockers may be potential confounding factors which should be adjusted.
Response: Thank you for the comments. As suggested, we have considered the factors, including aspirin, statins, and angiotensin receptor blockers in the Cox regressions. The relevant data were displayed in Table 2, Table 3, and Table 4 . Additionally, we have revised the relevant statements throughout all manuscript. (page 9-page 10) 2.
the pioglitazone exposure strength should be explained, did patients receive pioglitazone for 5 years in study group?
Response: Thank you for the suggestions. We have performed a dose-dependent analysis to determine whether pioglitazone exposure strength was associated with PD. The findings were presented in Table 4 . We have addressed relevant methodology in Methods as follows: "This study further conducted a dose-dependent analysis to investigate whether pioglitazone exposure strength was associated with PD. The cumulative defined daily dose (cDDD) was calculated as the sum of dispensed DDD of statins during 5-year study period in this study. We categorized the patients receiving pioglitazone into two levels according to the median dose (median cDDD=365)." (2nd paragraph, page 7)
VERSION 2 -REVIEW

REVIEWER
Magdalena Markowicz-Piasecka Medical University of Lodz REVIEW RETURNED 30-Jun-2018
GENERAL COMMENTS
All my suggestions previously stated have been corrected and addressed.
